M
27
-3
LB
66
-3
CRM
42
2
BBY
36
-2
FOX
70
4
CTAS
37
-2
AAPL
58
2
DLTR
44
-7
NFLX
72
2
D
23
-2
KIM
61
-3
ORLY
66
2
OXY
49
3
BRK.B
49
2
MMC
70
2
MCK
77
2
FTI
68
5
ADBE
49
4
ABT
60
-3
A
41
-2
M
27
-3
LB
66
-3
CRM
42
2
BBY
36
-2
FOX
70
4
CTAS
37
-2
AAPL
58
2
DLTR
44
-7
NFLX
72
2
D
23
-2
KIM
61
-3
ORLY
66
2
OXY
49
3
BRK.B
49
2
MMC
70
2
MCK
77
2
FTI
68
5
ADBE
49
4
ABT
60
-3
A
41
-2
Financhill
Back

Sage Therapeutics 10K Form

Sell
47

SAGE
Sage Therapeutics

Last Price:
$8.52
Seasonality Move:
6.64%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SAGE News And Ratings

See the #1 stock for the next 7 days that we like better than SAGE

SAGE Financial Statistics

Sales & Book Value

Annual Sales: $41.2M
Cash Flow: $-66.6M
Price / Cash Flow: 0
Annual Sales: $7.58
Price / Book: 1.09

Profitability

EPS (TTM): -6.59000
Net Income (TTM): $-400.7M
Gross Margin: $31.8M
Return on Equity: -63.59%
Return on Assets: -56.97%

Sage Therapeutics Earnings Forecast

Key Sage Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 12 years for SAGE is 77.10%.
  • The Selling, General & Administrative Expenses for SAGE have been equal to 524.74% of Gross Profit Margin.
  • The Research & Development expenses have been 547.72% of Revenue.
  • Per Share Earnings over the last 13 years have been positive in 2 years.

Sage Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SAGE
CUSIP: 78667J
Website: sagerx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.42
Quick Ratio: 7.17

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SAGE Technical Analysis vs Fundamental Analysis

Sell
47
Sage Therapeutics (SAGE) is a Sell

Is Sage Therapeutics a Buy or a Sell?

  • Sage Therapeutics stock is rated a Sell
    The current Sage Therapeutics [SAGE] share price is $8.53. The Score for SAGE is 47, which is 6% below its historic median score of 50, and infers higher risk than normal.